Trial Profile
Efficacy and Safety of XM22 compared to pegfilgrastim in patients with breast cancer receiving chemotherapy. A multinational, multicentre, randomised, double-blind controlled study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Apr 2015
Price :
$35
*
At a glance
- Drugs Lipegfilgrastim (Primary) ; Pegfilgrastim
- Indications Neutropenia
- Focus Pharmacogenomic; Pharmacokinetics; Therapeutic Use
- Sponsors BioGeneriX
- 20 Apr 2015 New trial record